Recent News and Articles on the Keywords: hiv + haart + 60,600  Related to the article below (Last Update: 8/7/2008)

Highly Active Antiretroviral Therapy Of Similar Benefit For HIV ... Science Daily (press release) - 7, 2008) ? Contrary to the belief that HIV-infected injection drug users (IDUs) receive less benefit from highly active antiretroviral therapy (HAART), ... Anti-HIV ?Drug Cocktails? Equally Effective in Patients with or ... National Institutes of Health (press release) HIV Expert Says 1 Step Down, 2 More To Go In Quest To Cure AIDS Science Daily (press release) Long-term HIV Treatment May Reduce Risk For Atherosclerosis Science Daily (press release) all 52 news articles » Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of ... MarketWatch - It is clear however, that HAART overwhelmingly provides substantial survival benefits to HIV patients. As with all medications, physicians and patients must ... Health Highlights: Aug. 6, 2008 Atlanta Journal Constitution GlaxoSmithKline Says Studies Show No Increased Risk Of Heart ... RTT News all 17 news articles » BBC News HIV treatment could reduce rate of new infections Canada.com, Canada - Aug 5, 2008 The project used "a novel mathematical model" to look at the potential effects of increasing highly active anti-retroviral therapy (HAART) treatment ... IAC: More HIV Treatment May Reduce Transmission Risk MedPage Today Africa: Aids 2008 Plenary Speakers Underscore Persistence of Hiv ... AllAfrica.com Kaiser Daily HIV/AIDS Report Summarizes Reports, Initiatives From ... Kaiser network.org Canoe.ca - DG News all 704 news articles » Anti-HIV 'Drug Cocktails' Equally Effective in Patients with or ... Kansas City infoZine, MO - 49 minutes ago However, some doctors have been reluctant to prescribe HAART to HIV-infected injection drug users because of concern that they may not fully benefit from ... MedPage Today IAC: HIV Cure Called More than Theoretical Possibility MedPage Today, NJ - The existence of those was discovered soon after the introduction of highly active anti-retroviral therapy (HAART) in the late 1990s. Because HAART did not ... IAC: Injection Drug Use No Bar to HIV Therapy MedPage Today all 2 news articles » NIH Study: AIDS Drug Cocktail ?Extremely Effective? for Injectable ... CQPolitics.com, DC - ?This paper provides important evidence for the value of routinely providing HAART therapy to HIV-infected injection drug users who need treatment ... Miami Herald Examines Research on Crack Users and HIV Kaiser network.org all 2 news articles » Urine biomarkers may predict cardiovascular disease in people on HAART Aidsmap, UK - Cardiovascular disease (CVD) is a growing concern as people with HIV live longer. Several studies have found an association between heart attacks and ... BBC News Expansion of ARV programmes could reduce new HIV infections Africa Science News Service, Kenya - Aug 5, 2008 ?We?ve known for some time that the expansion of coverage with HAART could help to reduce the number of new HIV infections. However, we were amazed at the ... The Past, Present, and Future of AIDS Journal of American Medical Association (subscription) Comment by Julie Davids Executive Director, CHAMP all 1,459 news articles » Slowing CD4 cell decline with IL-2 allows HAART to be deferred by ... Aidsmap, UK - Interleukin-2 (IL-2) therapy to prevent CD4 T-cell loss and defer HAART in antiretroviral naive HIV-1 infected patients - Interstart ANRS 119 trial. ... Treatment outcomes in Latin America, China and Botswana: successes ... Aidsmap Two novel immune therapies in early investigation: autologous ... Aidsmap all 3 news articles » Drug addicts benefit from HIV drugs, too: study Reuters UK, UK - Aug 3, 2008 ... HIV-infected injecting drug users may not be deriving the full benefits of HAART (HIV drugs)," Dr. Julio Montaner of the University of British Columbia ...

HIV infection: ethnic differences in response to HAART

Researchers from the University of Massachusetts and the University of Pennsylvania have shown that race/ethnicity is a predictor of plasma lipids in patients with HIV-1 on HAART ( Highly Active AntiRetroviral Therapy ).

The researchers, led by Andrea Foulkes and Muredach Reilly, examined the influence of racial/ethnic influences on plasma lipoproteins, and the genetic effects on lipids in patients with HIV-1.

In a cross-sectional analysis of 626 patients participating in several ongoing AIDS Clinical Trial Group studies, Foulkes and colleagues looked at the way that race/ethnicity, genetic variants of lipoproteins apoC-III/apoA-I, and protease inhibitors affected plasma lipids.

Overall, Black patients on HAART had a lipid profile that meant they were likely to be less prone to atheroma than White and Hispanic patients.
They also found that in Hispanic, but not in White or Black patients, certain genetic variants of apoC-III were associated with less dyslipidemia in patients exposed to protease inhibitor-containing highly active antiretroviral therapy.

HIV-1 infection has become a chronic, manageable condition for patients who have long-term access to highly active antiretroviral therapy.
However, in some patients, highly active antiretroviral therapy causes various metabolic complications, including the development of dyslipidemia.
Some protease inhibitors have been associated with elevated levels of cholesterol, triglyceride, and low high-density lipoprotein cholesterol.
Protease-based highly active antiretroviral therapy has also been associated with increased risk for cardiovascular disease, which could, it has been suggested, lead to a future epidemic of cardiovascular disease in patients with HIV-1 treated with this regimen long term.

These findings are believed to be the first evidence for race/ethnicity–specific differences in both the occurrence of dyslipidemia on antiretroviral therapy ( ART ) and the influence of genetic factors on the occurrence of protease inhibitor-related lipid abnormalities. But the authors stress that the findings do not imply that "race" per se is responsible for functional differences between gene variants. Rather, it is more likely that differences relate to either variation in the inheritance pattern of haplotye blocks of the lipoprotein apoC-III gene, which the authors found to vary with race/ethnicity, or to the confounding influences of additional environmental and/or genetic factors.

The authors also point out that strategies that identify individuals with HIV-1 at increased risk of antiretroviral therapy -related metabolic complications will improve the selection of appropriate antiretroviral regimens and preventive cardiovascular therapies, and ultimately may decrease the long-term cardiovascular risk of these patients.

Source: PLoS, 2006